HMGB1 and neoplasm: It has been found that Cabozantinib triggers the release of C-X-C motif chemokine ligand 12 (CXCL12) and high mobility group box 1 protein (HMGB1) from dying tumor cells, which mediate acute neutrophil mobilization and migration, contributing to an amplified anti-tumor response.